Patients receiving chemotherapy for advanced NSCLC or pancreatic ductal adenocarcinoma (PDAC) often experience pleural effusion, ascites or constipation secondary to opioid or 5‐HT3 antagonist treatment, which might contribute to bias in the measurement of muscle mass by DXA. Here, HTR3A is linked to pancreatic ductal adenocarcinoma.